Cancer treatment and survivorship statistics, 2014
暂无分享,去创建一个
A. Jemal | R. Siegel | A. Mariotto | C. DeSantis | C. Lin | J. Kramer | A. Robbins | K. Stein | Rick Alteri
[1] A. Cherry,et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. , 2005, Blood.
[2] D. Berry,et al. Effect of screening and adjuvant therapy on mortality from breast cancer. , 2006, The New England journal of medicine.
[3] P. Stephens,et al. Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary , 2013, Clinical Cancer Research.
[4] C. Ko,et al. Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] P. Warde,et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] S. Edge,et al. Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004-2006. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Jemal,et al. Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer , 2014, Cancer.
[8] P. Jain,et al. Richter's Transformation in Chronic Lymphocytic Leukemia Richter's Transformation in Chronic Lymphocytic Leukemia , 2022 .
[9] David Botstein,et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[10] Marilyn Stovall,et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Y. Yamada,et al. Ten‐year outcomes of high‐dose, intensity‐modulated radiotherapy for localized prostate cancer , 2011, Cancer.
[12] J. Hoffman-Censits,et al. Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer , 2013, Clinical Cancer Research.
[13] Julia H. Rowland,et al. Mental and Physical Health–Related Quality of Life among U.S. Cancer Survivors: Population Estimates from the 2010 National Health Interview Survey , 2012, Cancer Epidemiology, Biomarkers & Prevention.
[14] G. Andriole. Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer , 2013 .
[15] K. Dookeran,et al. Racial and Ethnic Differences in Breast Cancer Survival: How Much Is Explained by Screening, Tumor Severity, Biology, Treatment, Comorbidities, and Demographics? , 2008 .
[16] H. Brenner,et al. Quality of life among long-term (≥5 years) colorectal cancer survivors--systematic review. , 2010, European journal of cancer.
[17] Rebecca Smith-Bindman,et al. Racial and ethnic differences in breast cancer survival , 2008, Cancer.
[18] P. Conte,et al. Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer: Putting Safety Issues into Perspective , 2007, The breast journal.
[19] Disparities in breast cancer outcomes between Caucasian and African American women: a model for describing the relationship of biological and nonbiological factors , 2013, Breast Cancer Research.
[20] J. Hardcastle,et al. Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.
[21] G. Armstrong,et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. , 2013, JAMA.
[22] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[23] H. Kehlet,et al. Prevalence of and factors associated with persistent pain following breast cancer surgery. , 2009, JAMA.
[24] R. Jagsi,et al. Trends and variation in use of breast reconstruction in patients with breast cancer undergoing mastectomy in the United States. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] G. Gustafsson,et al. Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden , 2006, Cancer.
[26] L. Strobbe,et al. Effect of axillary lymph node dissection on prevalence and intensity of chronic and phantom pain after breast cancer surgery. , 2008, The journal of pain : official journal of the American Pain Society.
[27] A. D'Amico,et al. Androgen‐Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology , 2010, CA: a cancer journal for clinicians.
[28] P. Warde,et al. Treatment burden in stage I seminoma: a comparison of surveillance and adjuvant radiation therapy , 2013, BJU international.
[29] H. Kehlet,et al. Persistent postsurgical pain: risk factors and prevention , 2006, The Lancet.
[30] C. O’Malley,et al. Diabetes in elderly patients with breast cancer in the United States: An analysis of data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] M. Santoro,et al. Central role of RET in thyroid cancer. , 2013, Cold Spring Harbor perspectives in biology.
[32] P. Saylor,et al. Metabolic complications of androgen deprivation therapy for prostate cancer. , 2009, The Journal of urology.
[33] M. Aghili,et al. Clinical and pathological evaluation of patients with early and late recurrence of colorectal cancer , 2010, Asia-Pacific journal of clinical oncology.
[34] A. Niemierko,et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. , 2012, European urology.
[35] Prokar Dasgupta,et al. Recent advances in the diagnosis and treatment of bladder cancer , 2013, BMC Medicine.
[36] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[37] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[38] N. Keating,et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. , 2010, Journal of the National Cancer Institute.
[39] K. McGuire,et al. Are Mastectomies on the Rise? A 13-Year Trend Analysis of the Selection of Mastectomy Versus Breast Conservation Therapy in 5865 Patients , 2009, Annals of Surgical Oncology.
[40] N. Parr,et al. Long‐term changes in bone mineral density and predicted fracture risk in patients receiving androgen‐deprivation therapy for prostate cancer, with stratification of treatment based on presenting values , 2009, BJU international.
[41] S. Sindrup,et al. The postmastectomy pain syndrome: an epidemiological study on the prevalence of chronic pain after surgery for breast cancer , 2008, British Journal of Cancer.
[42] S. Bhatia. Disparities in cancer outcomes: Lessons learned from children with cancer , 2011, Pediatric blood & cancer.
[43] H. Sasaki,et al. Risk factors for lower limb lymphedema after lymph node dissection in patients with ovarian and uterine carcinoma , 2009, BMC Cancer.
[44] J. Griggs,et al. Use of radioactive iodine for thyroid cancer. , 2011, JAMA.
[45] R. Saskin,et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. , 2014, The Lancet. Oncology.
[46] Xianglin L. Du,et al. Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node‐positive, operable breast cancer , 2009, Cancer.
[47] G. Colditz,et al. Online Continuing Education Activity Article Title: American Cancer Society Lung Cancer Screening Guidelines Continuing Medical Education Accreditation and Designation Statement: Continuing Nursing Education Accreditation and Designation Statement: Educational Objectives: Activity Disclosures Acs Co , 2022 .
[48] F. Rosendaal,et al. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors , 2013, British Journal of Cancer.
[49] D. Hughes,et al. Weight Lifting for Women at Risk for Breast Cancer–Related Lymphedema: A Randomized Trial , 2011 .
[50] Dirk F Moore,et al. Outcomes of localized prostate cancer following conservative management. , 2009, JAMA.
[51] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[52] A. Bleyer. Young Adult Oncology: The Patients and Their Survival Challenges , 2007, CA: a cancer journal for clinicians.
[53] M. Goldfarb,et al. Well‐differentiated thyroid carcinoma: The role of post‐operative radioactive iodine administration , 2013, Journal of surgical oncology.
[54] L. Koniaris,et al. Florida bladder cancer trends 1981 to 2004: minimal progress in decreasing advanced disease. , 2008, The Journal of urology.
[55] J. Mohler. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[56] C. Pui,et al. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. , 2008, The Lancet. Oncology.
[57] Steve Scoppa,et al. Multiple Cancer Prevalence: A Growing Challenge in Long-term Survivorship , 2007, Cancer Epidemiology Biomarkers & Prevention.
[58] B. Coiffier,et al. State-of-the-art therapeutics: diffuse large B-cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] A. Polednak. Estimating the number of U.S. incident cancers attributable to obesity and the impact on temporal trends in incidence rates for obesity-related cancers. , 2008, Cancer detection and prevention.
[60] B. Newman,et al. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. , 2013, The Lancet. Oncology.
[61] F. Saad,et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.
[62] E. Feuer,et al. Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000–2020 , 2006, Cancer Causes & Control.
[63] Peter Baade,et al. A systematic review of the impact of stigma and nihilism on lung cancer outcomes , 2012, BMC Cancer.
[64] C. Audette,et al. The sexual health of women after gynecologic malignancy. , 2010, Journal of midwifery & women's health.
[65] Eric J Feuer,et al. Projections of the cost of cancer care in the United States: 2010-2020. , 2011, Journal of the National Cancer Institute.
[66] R. Huddart,et al. Comment on ‘Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors' , 2013, British Journal of Cancer.
[67] F. Behm,et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. , 1989, The New England journal of medicine.
[68] Ahmedin Jemal,et al. Childhood and adolescent cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[69] E. de Azambuja,et al. Improving quality of life after breast cancer: dealing with symptoms. , 2011, Maturitas.
[70] Michael B Atkins,et al. Which drug, and when, for patients with BRAF-mutant melanoma? , 2013, The Lancet. Oncology.
[71] P. Ganz,et al. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. , 2012, Journal of the National Cancer Institute.
[72] F. Frasca,et al. Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk Factors , 2013, Journal of cancer epidemiology.
[73] D. Brizel,et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .
[74] Jim C Hu,et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. , 2011, JAMA.
[75] James A Hanley,et al. 20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.
[76] P. Mauch,et al. Nodular lymphocyte-predominant hodgkin lymphoma. , 2007, Seminars in radiation oncology.
[77] J. Zajac,et al. Hematological changes during androgen deprivation therapy. , 2012, Asian journal of andrology.
[78] Andrew Ma,et al. Comparison of Cases Captured in the National Cancer Data Base with Those in Population-based Central Cancer Registries , 2013, Annals of Surgical Oncology.
[79] M. Brennan,et al. Uptake and predictors of post-mastectomy reconstruction in women with breast malignancy--systematic review. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[80] Karen R. Sepucha,et al. Are Patients Making High-Quality Decisions about Breast Reconstruction after Mastectomy? [Outcomes Article] , 2011, Plastic and reconstructive surgery.
[81] R. Fisher,et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.
[82] M. Graefen,et al. Updated assessment of neobladder utilization and morbidity according to urinary diversion after radical cystectomy: A contemporary US-population-based cohort. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[83] A. Zietman,et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. , 2013, The Lancet. Oncology.
[84] A. Bleyer,et al. The adolescence of young adult oncology. , 2009, Seminars in oncology.
[85] S. Groshen,et al. Long‐term outcome in patients with a Gleason score ≤6 prostate cancer treated by radical prostatectomy , 2011, BJU international.
[86] D. Rose,et al. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. , 2009, Journal of women's health.
[87] R. Capocaccia,et al. Estimation and projections of cancer prevalence from cancer registry data , 2002, Statistics in medicine.
[88] Stacey A. Kenfield,et al. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] L. Harlan,et al. Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[91] J. Cayuela,et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] E. Hill,et al. Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. , 2012, Blood.
[93] P. Johnstone,et al. Lymphedema: A primer on the identification and management of a chronic condition in oncologic treatment , 2009, CA: a cancer journal for clinicians.
[94] H. Kantarjian,et al. The biology and therapy of adult acute lymphoblastic leukemia , 2003, Cancer.
[95] S. L. Stewart,et al. Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin. , 2011, Journal of the American Academy of Dermatology.
[96] Gretchen L. Gierach,et al. Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients. , 2013, Journal of the National Cancer Institute.
[97] P. Kantoff,et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.
[98] W Lutzeyer,et al. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. , 1982, The Journal of urology.
[99] S. Loening,et al. Superficial bladder cancer: progression and recurrence. , 1983, The Journal of urology.
[100] A. Jemal,et al. Colorectal cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[101] Claire Schwab,et al. Acute lymphoblastic leukaemia. , 2011, Methods in molecular biology.
[102] M. Proschan,et al. Randomized Trials of Breast-Conserving Therapy Versus Mastectomy for Primary Breast Cancer: A Pooled Analysis of Updated Results , 2005, American journal of clinical oncology.